Patents by Inventor Lucas Rascon

Lucas Rascon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CLL-1 TARGETED IMMUNOTHERAPIES
    Publication number: 20260055192
    Abstract: The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory discase, and immunodeficiency, or condition associated therewith.
    Type: Application
    Filed: August 27, 2025
    Publication date: February 26, 2026
    Applicants: Regeneron Pharmaceuticals, Inc., Inhibrx Biosciences, Inc.
    Inventors: Jordan Jarjour, Mark Pogson, Wai-Hang Leung, Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan Eckelman
  • CD8-Binding Polypeptides and Uses Thereof
    Publication number: 20250320295
    Abstract: Provided herein are VHH-containing polypeptides that bind CD8. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: July 19, 2022
    Publication date: October 16, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, William Crago, Florian Sulzmaier, Lucas Rascon, Brendan P. Eckelman
  • CLL-1 targeted immunotherapies
    Patent number: 12421315
    Abstract: The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: September 23, 2025
    Assignees: Regeneron Pharmaceuticals, Inc., Inhibrx Biosciences, Inc.
    Inventors: Jordan Jarjour, Mark Pogson, Wai-Hang Leung, Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan P. Eckelman
  • USES OF PDL1-BINDING PROTEINS
    Publication number: 20250250349
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: November 22, 2024
    Publication date: August 7, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan R. Becklund, Rajay A. Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multivalent and multispecific OX40-binding fusion proteins
    Patent number: 12227584
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: February 18, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • CLEC12a Binding Polypeptides and Uses Thereof
    Publication number: 20250011436
    Abstract: Provided herein are VHH-containing polypeptides that bind CLEC12a. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: June 20, 2024
    Publication date: January 9, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan P. Eckelman
  • Multivalent and multispecific 41BB-binding proteins
    Patent number: 12187804
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: January 7, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • CLEC12a binding polypeptides and uses thereof
    Patent number: 12043667
    Abstract: Provided herein are VHH-containing polypeptides that bind CLEC12a. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: July 23, 2024
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan P. Eckelman
  • Multivalent and Multispecific 41BB-Binding Proteins
    Publication number: 20230416387
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: December 16, 2022
    Publication date: December 28, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • PDL1-binding proteins
    Patent number: 11566078
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: January 31, 2023
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • CLL-1 TARGETED IMMUNOTHERAPIES
    Publication number: 20220323496
    Abstract: The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
    Type: Application
    Filed: May 7, 2020
    Publication date: October 13, 2022
    Applicants: 2SEVENTY BIO, INC., INHIBRX, INC.
    Inventors: JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, LUCAS RASCON, ANGELICA SANABRIA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
  • Multivalent and Multispecific OX40-Binding Fusion Proteins
    Publication number: 20220106397
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Application
    Filed: August 10, 2021
    Publication date: April 7, 2022
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multivalent and multispecific OX40-binding fusion proteins
    Patent number: 11117972
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: September 14, 2021
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Hata, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • CLEC12a Binding Polypeptides and Uses Thereof
    Publication number: 20200347139
    Abstract: Provided herein are VHH-containing polypeptides that bind CLEC12a. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: May 1, 2020
    Publication date: November 5, 2020
    Applicant: Inhibrx, Inc.
    Inventors: Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan P. Eckelman
  • Multivalent and Multispecific 41BB-Binding Fusion Proteins
    Publication number: 20200199243
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: October 15, 2019
    Publication date: June 25, 2020
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multivalent and multispecific 41BB-binding fusion proteins
    Patent number: 10501551
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: December 10, 2019
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Hata, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux